POSTGRADUATE MEDICINE研究生医学
POSTGRADUATE MEDICINE(英文缩写 POSTGRAD MED),ISSN 0032-5481,eISSN 1941-9260,中文译名:研究生医学 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
发文量统计区间：2025-09-27 至 2026-09-27，按本站收录文献的发表日期统计。
期刊介绍
历年影响因子趋势
| JCR 数据年份 | 影响因子 | JCR 分区 |
|---|---|---|
| 2021 | 4.379 | Q2 |
| 2022 | 4.200 | Q2 |
| 2023 | 2.600 | Q1 |
| 2024 | 2.800 | Q1 |
| 2025 | 2.700 | Q2 |
POSTGRADUATE MEDICINE 最新收录文献
-
2. The association between atorvastatin use and prothrombin time, apolipoprotein A-I levels, and apolipoprotein B levels in patients with type 2 diabetes mellitus and no history of atherosclerotic cardiovascular diseases: a cross-sectional study.
PMID:日期:2026-09-11Recent observational studies have demonstrated an association between apolipoproteins and vitamin K-dependent coagulation factors. Further research investigating this association is required. This study aimed to assess the association between atorvastatin use and prothrombin time (PT), apolipoprotein A-I (ApoA-I) levels, and apolipoprotein B (ApoB) levels in type 2 diabetes mellitus (T2DM) patients without established atherosclerotic cardiovascular disease and to investigate the association between PT and these apolipoproteins. A cross-sectional study recruited 147 T2DM patients attending Family Medicine clinics at King Abdullah University Hospital and Jordan University of Science and Technology Health Care Center, 72 patients started receiving atorvastatin at least 6 months before the recruitment date (case group), and 75 patients were not on statins (control group). PT showed an inverse association with ApoB in both groups (case group: β = -0.09, 95% CI: -0.17 to -0.02, = 0.017; and control group: β = -0.08, 95% CI: -0.15 to -0.02, = 0.015). No significant association was observed between PT and ApoA-I. The inverse association between PT and ApoB may suggest a potential link between the reduction in ApoB levels, through atorvastatin use, and the modulation of coagulation pathways relevant to venous thrombosis, although this requires confirmation in future prospective studies.
-
3. Utility and practical application of at-home daily urine hormone monitoring to support health, nutrition, and exercise: illustrative case-based perspectives across the female lifespan.
PMID:日期:2026-09-08Delayed diagnosis and fragmented care remain persistent challenges across women's health, due in part to limitations in evaluating the dynamic female hormone profile. Current clinical approaches to hormonal assessment often rely on single timepoint assessments that fail to capture hormonal variability, leading to incomplete or misleading insight into hormonal health. Recent technological advancements now allow for quantitative measurement of key reproductive hormones in urine using smartphone-compatible, at-home devices, making daily hormone monitoring across the menstrual cycle and reproductive lifespan feasible. The purpose of this illustrative, case-based perspective is to provide insight into: 1) when and why comprehensive at-home, daily hormone monitoring could be implemented; 2) how comprehensive hormone monitoring gives insight into the health state of women at different reproductive stages; and 3) how such information can inform lifestyle or medical recommendations. Illustrative case-based examples are given to demonstrate the potential applications of comprehensive at-home, daily hormone monitoring across the reproductive lifespan, including low energy availability (LEA), postpartum return to exercise, polyendocrine metabolic ovarian syndrome (PMOS), and perimenopause. Across cases, daily monitoring of reproductive hormones revealed hormone patterns that were not identifiable using traditional methods. In many cases, clinically meaningful patterns of ovulatory function, luteal phase quality, or reproductive stage were identified within one to two cycles, allowing more individualized lifestyle or medical interventions to be implemented. Collectively, these illustrative cases demonstrate that, when integrated with comprehensive clinical assessment and practitioner expertise, daily hormone monitoring can provide actionable insight into female physiology, support earlier identification of hormonal dysregulation, and inform personalized medicine and lifestyle changes across the reproductive lifespan.
-
4. Waist circumference provides improved cardiometabolic discrimination compared with body mass index in psoriatic disease: discrimination and reclassification analyses.
PMID:日期:2026-08-30Patients with psoriatic disease present a distinctive metabolic phenotype, yet the optimal anthropometric marker to capture cardiometabolic risk remains unclear. We evaluated whether waist circumference provides superior cardiometabolic discrimination and reclassification compared with BMI in psoriatic disease. In this cross-sectional study, we assessed consecutive patients with psoriasis and/or psoriatic arthritis ( = 572). The primary outcome was clustered cardiometabolic burden (≥2 predefined cardiometabolic abnormalities). Waist circumference and BMI were compared using principal component analysis (PCA), ROC curves, Youden-derived sex-specific thresholds, and both categorical and continuous reclassification metrics (NRI and IDI), overall and stratified by sex. Additional sensitivity analyses used standard metabolic cutoffs (ATP III/IDF). Waist circumference and BMI showed the highest loadings on the first principal component representing the cardiometabolic axis, with a slightly higher contribution from waist circumference (loading 0.864 vs 0.826). Waist circumference showed modest but statistically significant improvement in discrimination compared with BMI for clustered cardiometabolic abnormalities (AUC 0.78 vs 0.73 for ≥2 factors, DeLong = 0.003; AUC 0.78 vs 0.71 for ≥3 factors, DeLong < 0.001). Waist circumference-derived thresholds provided incremental risk stratification beyond BMI, with consistent improvements in reclassification metrics across cardiometabolic burden definitions. Youden-derived thresholds (100 cm in men and 99 cm in women) showed better balance between sensitivity and specificity than ATP III and IDF criteria, while maintaining clinically relevant likelihood ratios. Sensitivity analyses incorporating waist-to-height ratio showed similar findings without additional benefit over waist circumference alone. Waist circumference provided consistently better overall cardiometabolic discrimination than BMI and may represent a more informative anthropometric marker for cardiometabolic risk assessment in psoriatic disease.
-
5. {"_":"Prognostic performance of APUA, APUA-RO, and CURB-65 scores in patients with critical pneumonia.","sub":["2"]}
PMID:日期:2026-08-29Severe pneumonia requiring intensive care unit (ICU) admission is associated with high short-term mortality. Early risk stratification in emergency settings is essential to guide clinical decisions. The APUA and APUA-RO scores have been proposed as simplified prognostic tools, but their performance in critically ill pneumonia patients remains unclear. To compare the prognostic performance of APUA, APUA-RO, and CURB-65 scores in emergency department patients with pneumonia and ICU indications. This retrospective, single-center study included adult patients with community-acquired pneumonia who were evaluated for ICU admission in the emergency department between 1 September 2024, and 1 September 2025. Demographic, clinical, and laboratory data were extracted from electronic medical records. APUA, APUA-RO, and CURB-65 scores were calculated at presentation. The primary outcome was 30-day in-hospital mortality. Discriminative ability was assessed using receiver operating characteristic curves and area under the curve (AUC) analysis. Multivariable logistic regression was performed to identify independent predictors of mortality. Among 191 patients, 121 (63.4%) died within 30 days. Non-survivors had higher respiratory rates, CRP, LDH, creatinine, and pneumonia severity scores (APUA, APUA-RO, CURB-65; all < .001). All three scores demonstrated moderate discriminative performance, with AUCs of 0.732 for APUA, 0.765 for APUA-RO, and 0.697 for CURB-65. Model performance was highest for APUA-RO (AUC 0.825, sensitivity 87.6%, specificity 55%). Pairwise AUC comparisons did not reach statistical significance, although APUA-RO showed a trend toward better performance. Multivariable analysis confirmed that malignancy and higher pneumonia severity scores were independent predictors of mortality. All three severity scores demonstrated moderate discriminative ability for predicting 30-day mortality in critically ill pneumonia patients. Among them, APUA-RO showed the highest prognostic performance, although its overall discrimination remained moderate. Therefore, these scores may assist, but should not replace, clinical judgment when assessing critically ill patients. Prospective multicenter validation is warranted.
-
6. Oral semaglutide for obesity: clarifying comparative evidence and real-world applicability.
PMID:日期:2026-08-20该文献暂无摘要。
-
9. Ponatinib in CML and Ph+ ALL: balancing high efficacy with vascular safety.
PMID:日期:2026-08-01Chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) are driven by the BCR:ABL1 fusion and remain highly responsive to tyrosine kinase inhibitors (TKIs). Ponatinib, a third-generation TKI, uniquely retains activity against the T315I 'gatekeeper' mutation and most other BCR:ABL1 variants, producing deep cytogenetic and molecular responses in resistant CML and improving survival in Ph+ ALL. Across the PACE and OPTIC programs, frontline Ph+ ALL combinations (hyper-CVAD- and blinatumomab-based), and real-world cohorts, ponatinib demonstrates robust antileukemic efficacy in diverse settings and after multiple prior TKIs. However, its multikinase profile confers a clinically meaningful risk of arterial occlusive events (AOEs)-including coronary, cerebrovascular, and peripheral arterial complications-whose incidence is shaped by baseline cardiovascular risk and overall drug exposure. Mechanistic studies suggest that endothelial dysfunction, pro-inflammatory signaling, impaired nitric oxide bioavailability, and microvascular rarefaction contribute to ponatinib-associated vascular toxicity. Clinically, response-based dosing-such as step-down from 45→30→15 mg in CML or 30→15 mg in Ph+ ALL upon molecular milestones-preserves efficacy while reducing exposure-related AOE risk, though events are not eliminated. Emerging cardio-oncology strategies can further mitigate harm: baseline risk stratification (e.g. SCORE2/SCORE2-OP, HFA-ICOS), aggressive management of blood pressure and lipids, selective antiplatelet prophylaxis in high-risk profiles, and close longitudinal surveillance. Overall, contemporary evidence supports ponatinib as a high-potency option for T315I disease and multi-tyrosine kinase inhibitor (TKI) resistance, and as a practical component of modern Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) therapy, provided that dosing is individualized and cardiovascular risk is proactively managed. Future priorities include refining patient selection, validating preventive cardio-oncology bundles, and defining minimal-effective exposure thresholds that sustain durable disease control with the lowest feasible vascular liability.
-
10. Managing patients with cardiovascular-kidney-metabolic syndrome: a guideline-driven practical guide for primary care physicians.
PMID:日期:2026-08-01Cardiovascular-kidney-metabolic (CKM) syndrome is a systemic disorder characterized by an overall reduction in cardiovascular health that occurs as a result of the development of ≥2 cardiovascular, kidney, or metabolic risk factors. Prevalence of CKM syndrome and its contributing conditions is rising, carrying an associated increase in excess morbidity, premature mortality, and direct and indirect health-related expenditures for patients, particularly for individuals with adverse social determinants of health. The growing body of evidence supporting CKM syndrome as a single, multifactorial disease underscores the importance of implementing an overarching, interdisciplinary therapeutic approach for the prevention and management of each facet of the disease. The recent development of several therapies with multiple benefits for cardiovascular, kidney, and metabolic health provides an important opportunity to facilitate the development of treatment plans that address the root cause of CKM syndrome for patients in early stages and to alleviate symptoms, delay progression, and improve quality of life in later stages of the syndrome. These developments provide a challenge for primary care physicians (PCPs) to ensure they are managing patients at their current disease stage, with the most appropriate combination of therapies available. This review aims to provide PCPs with a guideline-driven, practical guide to facilitate these decisions on the most appropriate management path for different scenarios for patients with CKM syndrome.